title: [Anti-tumor necrosis factor-α medications and pregnancy].
authors.affiliation: Servicio de Farmacología Clínica, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España.
authors.forename: Petru Cristian
authors.initials: PC
authors.lastname: Simon
authors.forename: Antonio
authors.initials: A
authors.lastname: Vallano
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology / Q000209:etiology; D000022:Abortion, Spontaneous / Q000139:chemically induced / Q000453:epidemiology; D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001688:Biological Products / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D000068582:Certolizumab Pegol; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D004348:Drug Labeling; D000068800:Etanercept; D005260:Female; D005333:Fetus / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007231:Infant, Newborn; D000069285:Infliximab; D008431:Maternal-Fetal Exchange; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011263:Pregnancy Trimester, Third; D011644:Puerperal Disorders / Q000139:chemically induced / Q000453:epidemiology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012042:Registries; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014611:Vaccination
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept; D000068582:Certolizumab Pegol